Author

Jose-Fernando Barba-Gómez

Observed names: Barba-Gómez Jose-Fernando, Jose-Fernando Barba-Gomez, Jose-Fernando BarbaGómez

Observed institution: GlaxoSmithKline (Belgium)

OpenAlex ID: A5000674729

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

2022 · Ana Strezova, Javier Diez-Domingo, et al. · Open Forum Infectious Diseases · 103

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

2021 · Céline Boutry, Andrew Hastie, et al. · Clinical Infectious Diseases · 96

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials

2019 · David O. Willer, Lidia Oostvogels, et al. · Vaccine · 30

Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients

2020 · Josephine Ocran-Appiah, Céline Boutry, et al. · Vaccine · 16

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults by Region: Results of the Phase 3 ZOE-50 Trial

2015 · Anthony L Cunningham, Roman Chlibek, et al. · Open Forum Infectious Diseases · 1

Works count: 5

Citation count: 246

H-index: 4

I10-index: 4